Paul LePage: CONTROLLED SUBSTANCES PRESCRIPTION MONITORING PROGRAM

In 2017, Bipartisan Majorities of the House and Senate Overrode LePage’s Veto Of Legislation To Allow Methadone Treatment Facilities To Be Entered Into The Controlled Substances Prescription Monitoring Program With Patients’ Consent. In June 2017, the House overrode LePage’s veto of LD1619 by a 143-0 vote and the Senate by a 34-0 vote. LD 1619 “allows for the name of a methadone treatment facility and dosage information regarding methadone for the treatment of opioid dependency to be entered into the Controlled Substances Prescription Monitoring Program if a patient has given consent to the facility and the information is disclosed only during a medical emergency and only to medical personnel involved in treating the patient. Any disclosure of methadone dosage information is subject to 42 Code of Federal Regulations, Section 2.32. A patient's dosage information must be entered into the Controlled Substances Prescription Monitoring Program when treatment begins, 90 days after that, and then every 180 days. The Department of Health and Human Services must amend the contract amendment to ensure the required enhancement to the Controlled Substances Prescription Monitoring Program. The department must convene a stakeholder group to advise on the criteria for the enhancement and stakeholders must include methadone providers and providers of emergency services. The department must submit a progress report on implementation of the enhancement to the Joint Standing Committee on Health and Human Services by January 30, 2018.” [Joint Standing Committee on Health and Human Services, Summaries of Bills, LD 1619, August 2017; State of Maine Legislature, LD 1619, Roll Call #369, 6/21/17]

  • Maine’s Prescription Monitoring Program Tracked Controlled Prescription Drugs In The State Of Maine In Order To Prevent And Detect Misuse Of Prescription Drugs. “What is a Prescription Monitoring Program (PMP)? A Prescription Monitoring Program (PMP; sometimes called a Prescription Drug Monitoring Program, or PDMP) is a state-run electronic database that tracks controlled prescription drugs that are dispensed to patients within the state. A PMP is a tool that prescribers, pharmacists, and other healthcare and public health professionals can use to address misuse, abuse, and diversion of prescription drugs. Why does Maine have a PMP? The Maine PMP was created to prevent and detect the misuse, abuse, and diversion of prescription drugs in Maine.” [Maine Substance Abuse and Mental Health Services, accessed 5/2/19]

In 2013, LePage Refused to Sign Bipartisan Legislation Instructing the Substance Abuse Services Commission to Develop a Process to Increase Registration in the Controlled Substances Prescription Monitoring Program. LD388 “requires the Substance Abuse Services Commission to develop a process to increase registration in the Controlled Substances Prescription Monitoring Program through professional licensing boards and to develop strategies to promote the use of the program by prescribers. The Substance Abuse Services Commission is required to report its findings, recommendations and any suggested legislation to the Joint Standing Committee on Health and Human Services by January 1, 2014.” The House passed LD 388 by a 138-0 vote. The Senate passed the bill on 5/8/13 and it became law without Governor LePage’s signature. [Morning Sentinel, 2/27/13; State of Maine Legislature, LD 388, Roll Call #71, 5/2/13; State of Maine Legislature, Summary of LD 388, 5/20/13]

Source report (PDF)